Abstract:Purpose/Objective(s)To evaluate hypoxia in esophageal squamous cell carcinoma (SCC) with (18F-FETNIM PET/CT. We determined an imaging threshold for hypoxia, quantified the spatiotemporal variability of hypoxia in untreated tumor, and evaluated the ability of 18F-FETNIM PET to predict clinical response following concurrent chemoradiotherapy (CCRT).Materials/MethodsTwenty-eight consecutive patients with inoperable SCC of the esophagus were consecutively accrued between April 2007 and June 2010. The first 10 patients received two pretreatment 18F-FETNIM-PET/CT scans on separate days. The remaining 18 patients only underwent 18F-FETNIM-PET/CT once before CCRT. The ratio of the maximum standardized uptake value (SUVmax) of 336 normal tissue regions (i.e., heart, lung, brain or muscle) to the mean standardized uptake value (SUVmean) of the respective patient's spleen was calculated, and the imaging threshold for hypoxia defined as the level of uptake demonstrated by less than 5% of tissue regions. Among the patients with two pretreatment scans, each pair of scans was compared with respect to location and intensity of uptake to assess for baseline spatiotemporal variability. Logistic regression analysis was used to determine whether pretreatment imaging characteristics are predictive of clinical response.ResultsThe mean and median ratios of the SUVmax of tissue:SUVmean of spleen were nearly identical, and 95% of the ratios fell below 1.3. The mean Dice similarity coefficient for the hypoxic volumes on pretreatment PET scans acquired in the same patient on different days was 0.12 (range, 0.05-0.21). Individuals' tumor SUVmax and SUVmean did not vary significantly, but on average, the geometric centers of hypoxic regions shifted 15 mm (range, 8-20 mm) from the first pretreatment scan to the second. SUVmax was the imaging characteristic most predictive of treatment response (p = 0.041), with high SUVmax associated with poor clinical response.Conclusions18F-FETNIM PET/CT scan depict hypoxia in esophageal SCC. Prior to CCRT, tumor hypoxia demonstrates spatial variability on different days, though overall 18F-FETNIM uptake remains similar. Baseline SUVmax may be predictive of treatment response. Purpose/Objective(s)To evaluate hypoxia in esophageal squamous cell carcinoma (SCC) with (18F-FETNIM PET/CT. We determined an imaging threshold for hypoxia, quantified the spatiotemporal variability of hypoxia in untreated tumor, and evaluated the ability of 18F-FETNIM PET to predict clinical response following concurrent chemoradiotherapy (CCRT). To evaluate hypoxia in esophageal squamous cell carcinoma (SCC) with (18F-FETNIM PET/CT. We determined an imaging threshold for hypoxia, quantified the spatiotemporal variability of hypoxia in untreated tumor, and evaluated the ability of 18F-FETNIM PET to predict clinical response following concurrent chemoradiotherapy (CCRT). Materials/MethodsTwenty-eight consecutive patients with inoperable SCC of the esophagus were consecutively accrued between April 2007 and June 2010. The first 10 patients received two pretreatment 18F-FETNIM-PET/CT scans on separate days. The remaining 18 patients only underwent 18F-FETNIM-PET/CT once before CCRT. The ratio of the maximum standardized uptake value (SUVmax) of 336 normal tissue regions (i.e., heart, lung, brain or muscle) to the mean standardized uptake value (SUVmean) of the respective patient's spleen was calculated, and the imaging threshold for hypoxia defined as the level of uptake demonstrated by less than 5% of tissue regions. Among the patients with two pretreatment scans, each pair of scans was compared with respect to location and intensity of uptake to assess for baseline spatiotemporal variability. Logistic regression analysis was used to determine whether pretreatment imaging characteristics are predictive of clinical response. Twenty-eight consecutive patients with inoperable SCC of the esophagus were consecutively accrued between April 2007 and June 2010. The first 10 patients received two pretreatment 18F-FETNIM-PET/CT scans on separate days. The remaining 18 patients only underwent 18F-FETNIM-PET/CT once before CCRT. The ratio of the maximum standardized uptake value (SUVmax) of 336 normal tissue regions (i.e., heart, lung, brain or muscle) to the mean standardized uptake value (SUVmean) of the respective patient's spleen was calculated, and the imaging threshold for hypoxia defined as the level of uptake demonstrated by less than 5% of tissue regions. Among the patients with two pretreatment scans, each pair of scans was compared with respect to location and intensity of uptake to assess for baseline spatiotemporal variability. Logistic regression analysis was used to determine whether pretreatment imaging characteristics are predictive of clinical response. ResultsThe mean and median ratios of the SUVmax of tissue:SUVmean of spleen were nearly identical, and 95% of the ratios fell below 1.3. The mean Dice similarity coefficient for the hypoxic volumes on pretreatment PET scans acquired in the same patient on different days was 0.12 (range, 0.05-0.21). Individuals' tumor SUVmax and SUVmean did not vary significantly, but on average, the geometric centers of hypoxic regions shifted 15 mm (range, 8-20 mm) from the first pretreatment scan to the second. SUVmax was the imaging characteristic most predictive of treatment response (p = 0.041), with high SUVmax associated with poor clinical response. The mean and median ratios of the SUVmax of tissue:SUVmean of spleen were nearly identical, and 95% of the ratios fell below 1.3. The mean Dice similarity coefficient for the hypoxic volumes on pretreatment PET scans acquired in the same patient on different days was 0.12 (range, 0.05-0.21). Individuals' tumor SUVmax and SUVmean did not vary significantly, but on average, the geometric centers of hypoxic regions shifted 15 mm (range, 8-20 mm) from the first pretreatment scan to the second. SUVmax was the imaging characteristic most predictive of treatment response (p = 0.041), with high SUVmax associated with poor clinical response. Conclusions18F-FETNIM PET/CT scan depict hypoxia in esophageal SCC. Prior to CCRT, tumor hypoxia demonstrates spatial variability on different days, though overall 18F-FETNIM uptake remains similar. Baseline SUVmax may be predictive of treatment response. 18F-FETNIM PET/CT scan depict hypoxia in esophageal SCC. Prior to CCRT, tumor hypoxia demonstrates spatial variability on different days, though overall 18F-FETNIM uptake remains similar. Baseline SUVmax may be predictive of treatment response.

Development of 18F-Fluoromisonidazole Hypoxia PET/CT Diagnostic Interpretation Criteria and Validation of Interreader Reliability, Reproducibility, and Performance

The optimal 18F-fluoromisonidazole PET threshold to define tumor hypoxia in preclinical squamous cell carcinomas using pO2 electron paramagnetic resonance imaging as reference truth

18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: A comparison with 18F-FMISO

Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts

68Ga-FAPI PET/CT Interobserver Agreement on Tumor Assessment: An International Multicenter Prospective Study

Tumor Hypoxia on 18F-fluoromisonidazole Positron Emission Tomography and Distant Metastasis From Head and Neck Squamous Cell Carcinoma

18F-HX4/18F-FMISO-based micro PET for imaging of tumor hypoxia and radiotherapy-associated changes in mice

Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats

18F-HX4 Hypoxia Imaging with PET/CT in Head and Neck Cancer

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.

Is there a role for [18F]-FMISO PET to guide dose adaptive radiotherapy in head and neck cancer? A review of the literature

18 F-Fluorination of Nitroimidazolyl-Containing Sultone: A Direct Access to a Highly Hydrophilic Radiotracer for High-Performance Positron Emission Tomography Imaging of Hypoxia

Measuring tumor hypoxia with ¹⁸F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study.

Positron Emission Tomography Imaging of Tumor Hypoxia

Local relapse of nasopharyngeal cancer and Voxel-based analysis of FMISO uptake using PET with semiconductor detectors

Hypoxia Predicts Favorable Response to Carbon Ion Radiotherapy in Non-Small Cell Lung Cancer (NSCLC) Defined by 18F-FMISO Positron Emission Tomography/computed Tomography (PET/CT) Imaging

[ 18 F]FMISO-PET imaging reveals the role of hypoxia severity in checkpoint blockade response

Improved Automated Production of 18F-FMISO and Its Tumor Hypoxia Imaging by Micro-PET/CT

Measuring Tumor Hypoxia with 18F-FETNIM PET in Esophageal Squamous Cell Carcinoma: A Pilot Clinical Study

The significance of partial volume effect on the estimation of hypoxic tumour volume with [18F]FMISO PET/CT

(18)F-Misonidazole PET Imaging of Hypoxia in Micrometastases and Macroscopic Xenografts of Human Non-Small Cell Lung Cancer: a Correlation with Autoradiography and Histological Findings.